Immix Biopharma (IMMX) Cash from Operations (2021 - 2026)

Immix Biopharma has reported Cash from Operations for 6 years, with the latest figure at 9827193.0 in Q1 2026.

• Quarterly Cash from Operations fell 483.17% year-over-year to 9827193.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 32072357.0 (down 157.54% YoY) and the FY2025 annual result came in at 23930304.0, down 63.96% from the prior year.
• Cash from Operations rose to 9827193.0 in Q1 2026 per IMMX's latest filing, from 11029607.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 547066.0 in Q2 2022 and troughed at 11029607.0 in Q4 2025.
• A 5-year average of 3948961.18 and a median of 3515346.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 2781.24% in 2022, then jumped 55.97% in 2025.
• Over 5 years, Cash from Operations stood at 3903926.0 in 2022, then soared by 31.42% to 2677437.0 in 2023, then jumped by 44.87% to 1476198.0 in 2024, then sank by 647.16% to 11029607.0 in 2025, then grew by 10.9% to 9827193.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 9827193.0, 11029607.0, and 5905776.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.